Literature DB >> 17146283

Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis.

Lee J Martin1.   

Abstract

The causes of the selective neurodegeneration in Parkinson disease (PD) and amyotrophic lateral sclerosis (ALS) are unknown and commonalities among these and other age-related neurodegenerative diseases continue to be sought. Morphologic, biochemical, molecular genetic, and cell/animal model studies suggest that mitochondria might be a convergence point for neurodegeneration. The functions and properties of mitochondria might render subsets of selectively vulnerable neurons intrinsically susceptible to cellular aging and stress. In PD, mutations in putative mitochondrial proteins have been identified recently and mitochondrial DNA mutations have been found in nigral neurons. In ALS, changes occur in mitochondrial respiratory chain enzymes and in mitochondrial cell death proteins, indicative of an activation of programmed cell death pathways. Mouse models are beginning to reveal possible principles governing the biology of selective neuronal vulnerability that implicate mitochondria in neuronal death processes ranging from apoptosis to necrosis. This review presents how malfunctioning mitochondria might contribute to neuronal death in PD and ALS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17146283     DOI: 10.1097/01.jnen.0000248541.05552.c4

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  31 in total

Review 1.  Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.

Authors:  Lee J Martin
Journal:  IDrugs       Date:  2010-08

Review 2.  Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders.

Authors:  Richard E Frye; Daniel A Rossignol
Journal:  Pediatr Res       Date:  2011-05       Impact factor: 3.756

Review 3.  ATP-sensitive potassium channels: novel potential roles in Parkinson's disease.

Authors:  Jie Zeng; Gang Wang; Sheng-Di Chen
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

Review 4.  Delivery of drugs and macromolecules to mitochondria.

Authors:  Abhijit Mukhopadhyay; Henry Weiner
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

Review 5.  Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

Authors:  Jason R Thonhoff; Luis Ojeda; Ping Wu
Journal:  Curr Stem Cell Res Ther       Date:  2009-09       Impact factor: 3.828

Review 6.  Mitochondrial medicine for aging and neurodegenerative diseases.

Authors:  P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2008-06-20       Impact factor: 3.843

7.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

8.  Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson's disease.

Authors:  Gaurav Patki; Yi Che; Yuen-Sum Lau
Journal:  Front Aging Neurosci       Date:  2009-12-11       Impact factor: 5.750

9.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

10.  Inducible nitric oxide synthase is present in motor neuron mitochondria and Schwann cells and contributes to disease mechanisms in ALS mice.

Authors:  Kevin Chen; Frances J Northington; Lee J Martin
Journal:  Brain Struct Funct       Date:  2009-11-04       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.